Robert Coleman, MD @TheUSONetwork @elevationonc #solidtumors Elevation Oncology and US Oncology Research Announce Collaboration in the Phase 2 CRESTONE Study

Robert Coleman, MD @TheUSONetwork @elevationonc #solidtumors Elevation Oncology and US Oncology Research Announce Collaboration in the Phase 2 CRESTONE Study

User Photo
Cancer-News

2 weeks
29 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer U.S. Oncology Research discusses Elevation Oncology and US Oncology Research Announce Collaboration to Expand Genomic Testing of Solid Tumors and Local Site Activation in Support of the Phase 2 CRESTONE Study.

US Oncology Research serves approximately 60 research sites and more than 165 locations, managing about 400 active trials at any given time.

NEW YORK and THE WOODLANDS, Texas, Sept. 30, 2020 /PRNewswire/ — Elevation Oncology, a biopharmaceutical clinical-stage company focusing on the production of precise medicines for genomically identified cancer patients, and US Oncology Research, one of the largest community-based oncology site management organizations in the United States, today announced an agreement to use the US Oncology Research.  

Across all cancer research sites operated by US Oncology Research, the STAR platform easily opens and activates clinical trials. STAR is an operational model that facilitates upfront pre-screening of potentially qualifying subjects and only opens locations where subjects are identified. When a potential STAR trial patient is found at a hospital, the practice is trained in the trial specifics, and the study is opened at the place where the patient will be handled within a two-week span.

US Oncology Study encourages practices to give patients in their local areas access to the new cancer clinical trial options, creating the potential for improved results and leading to the advancement of cancer care. Approximately 60 testing sites and more than 165 locations support US Oncology Testing, handling around 400 active trials at any given time. This range of coverage, and dedication to cross-disciplinary cooperation between facilities and individual specialties, makes US Oncology Research ideally positioned to accelerate the clinical production of precision medicines targeting rare genomic alterations.

For more information about the CRESTONE research, patients and doctors can visit www.nrg1fusion.com or www. ClinicalTrials.gov under the NCT number NCT04383210.
Up Next Autoplay
>